GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Nektar Therapeutics (NKTR) [hlAlert]

Rating:
Buy NKTR
up 112.77 %

Nektar Therapeutics (NKTR) rated Buy with price target $15 by Morgan Joseph

Posted on: Wednesday,  Mar 3, 2010  8:25 AM ET by Morgan Joseph

Morgan Joseph rated Buy Nektar Therapeutics (NASDAQ: NKTR) on 03/03/2010. Previously Morgan Joseph rated Buy Nektar Therapeutics (NASDAQ: NKTR) on 03/24/2009.,
when the stock price was $5.09. Since then, Nektar Therapeutics has gained 112.77% as of 12/07/2015's recent price of $10.83.
If you would have followed the previous Morgan Joseph's recommendation on NKTR, you would have gained 112.77% of your investment in 2449 days.

Nektar Therapeutics is a biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. The Company?s product pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Nektar?s research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. It creates its drug candidates by using its chemistry platform to modify the chemical structure of drugs using polymer conjugates. Nektar?s drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Morgan Joseph is committed to providing timely, objective and actionable investment advice on the companies and securities we follow. Our team of equity analysts covers a growing universe of stock issues across a broad range of industry sectors. As a middle market-focused firm, our approach is not to publish research on as many companies as possible within a number of industry sectors. Rather, our research analysts distinguish themselves by zeroing in on quality companies with growth prospects or which present special situations. These companies often lack a research following. This enables our analysts to provide insight to investors in companies that are not well understood nor fairly valued.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/3/2010 8:25 AM Buy
None
12.76 15.00
as of 12/31/2010
1 Week down  -13.12 %
1 Month down  -12.23 %
3 Months down  -24.71 %
1 YTD up  19.31 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/22/2009 8:25 AM Buy
None
10.29 12.00
6/19/2009 8:25 AM Buy
None
6.04 9.00
3/24/2009 8:25 AM Buy
None
5.09 7.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy